<DOC>
	<DOCNO>NCT00162760</DOCNO>
	<brief_summary>The goal study determine whether thalidomide stop progression fibrosis IPF . The primary objective study determine safety , feasibility efficacy 400 mg thalidomide administer daily one year patient idiopathic pulmonary fibrosis ( IPF ) fail candidate treatment corticosteroid and/or cytotoxic drug . The study population consist patient biopsy-proven moderate severe IPF fail candidate standard therapy corticosteroid and/or cytotoxic drug .</brief_summary>
	<brief_title>Treatment Idiopathic Pulmonary Fibrosis With Thalidomide</brief_title>
	<detailed_description>This unmasked Phase II , safety efficacy trial subject biopsy-proven IPF fail candidate standard therapy corticosteroid and/or cytotoxic drug . The study doctor interested study effect oral drug Thalomid ( R ) IPF . Thalomid ( R ) ( thalidomide ) approve medication Hansen 's disease ( leprosy ) . It know anti-inflammatory effect effect fibrosis . It hop Thalomid ( R ) may prevent progression IPF . Thalidomide investigational use , mean approved U.S. Food Drug Administration ( FDA ) treatment IPF . The age range study 50-80 year , inclusive . There 6 visit 12 month period . These visit include physical exam , pregnancy test ( applicable ) , several symptom scale questionnaires pulmonary fibrosis , pulmonary function test , x-rays , peripheral nerve testing , blood test include arterial blood gas measurement . You give medication capsule form every 28 day year . There set schedule increase dos thalidomide every 2 week reach 400 mg. dose study . A stool softener also provide participant . All subject must read , sign follow manual precaution prepare Celgene , manufacturer Thalomid ( R ) , enrol study . This manual , contain S.T.E.P.S . ( R ) precaution , give participant . This study conduct Johns Hopkins Medical Institutions locate Baltimore , Maryland .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Clinical history consistent IPF great equal 3 month duration le 5 year . Documented IPF UIP histologic examination surgical lung biopsy confirm study physician ( RT ) . High resolution CT ( HRCT ) chest consistent IPF ( bibasilar reticular abnormality minimal ground glass opacity ) determine study physician ( KMH ) . Failure &gt; /= 10 % increase FVC prior adequate treatment corticosteroid and/or cytotoxic drug , intolerance drug preclude use . FVC &gt; /= 40 % &lt; /= 90 % predict screening . DLCo &gt; /= 25 % predict screen Oxygen saturation &gt; /= 88 % room air &lt; /= 2L oxygen screening . Age 5080 inclusive Ability understand sign inform write consent form comply study guideline Known etiology ILD ( e.g . sarcoid , hypersensitivity pneumonitis , BOOP etc . ) Clinically significant toxic environmental exposure respiratory irritant ( e.g . drug , asbestosis , radiation etc . ) Diagnosis collagen vascular disease . Obstruction PFTs , define FEV1/FVC &lt; 0.6 . Active infection End stage coronary artery disease , congestive heart failure cor pulmonale History significant peripheral vascular disease History peripheral neuropathy History clinically significant obstructive sleep apnea History poorly control diabetes Pregnant lactate woman Abnormal laboratory define : WBC &lt; 2300/mm3 , HCT &lt; 30 % &gt; 55 % , PLT &lt; 100k/mm3 . creatinine &gt; 1.5 , AST ALT &gt; 3x normal , total bilirubin &gt; 1.5 . Current enrollment another protocol IPF Prednisone use &gt; 15 mg day 4 week prior start trial . Cytotoxic drug ( cyclophosphamide , azathioprine , colchicine , cyclosporine , interferongamma ) 6 week prior screen . Patients require chronic narcotic analgesic . Patients unable give inform consent . Patients unable comply requirement trial . Patients know allergy/intolerance thalidomide ; Patients predict life expectance le 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>